Press Releases

DarioHealth Enters Into a Partnership With Vitality to Accelerate Penetration Into the Self-insured Employer Market

Mar 24, 2020

NEW YORK, March 24, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario") a pioneer in the global digital therapeutics market, announced today that it has entered into a partnership with Vitality Group, a global health and wellness company committed to making people healthier. Under the partnership, Vitality will integrate Dario's digital therapeutics for chronic conditions into its current wellness solution platform and co-market the Dario solution to Vitality's existing client base. In conjunction with the partnership, Dario granted Vitality warrants that will become exercisable dependent on the success of the partnership over the next four years, beginning in 2020.


DarioHealth Logo


DarioHealth's digital therapeutics platform is designed to assist its members in most effectively managing and preventing chronic health conditions, such as prediabetes, diabetes, hypertension and obesity through real-time, personalized health data and analysis, along with individual digital and human coaching by wellness professionals. As part of the Vitality program, employees receive personalized and dynamic health recommendations and resources specific to their needs in a way that meets them where they are in their health journey, while also providing employers the opportunity to amplify their own benefits and programs. These offerings are supported by Vitality's proven expertise in behavioral science and incentive strategies to help employees overcome common decision errors.

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today's day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease data management, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel.

For more information, visit  

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, when the Company discusses that Vitality will integrate the Company's digital therapeutics for chronic conditions into its current wellness solution platform and co-market the Company's Dario solution to Vitality's existing client base, and that the partnership is intended to accelerate the Company's penetration into the self-insured employer market, it is using forward looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact: 
Claudia Levi 
Content & Communications Manager

Media Inquiries:
Investor Relations Contact:
Matthew Picciano

SOURCE DarioHealth Corp.